OXiGENE Announces Second Quarter 2009 Earnings Conference Call and Webcast


SOUTH SAN FRANCISCO, Calif., July 24, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer and eye diseases, will report
second quarter 2009 results on Thursday, July 30, 2009. A conference call and
webcast hosted by OXiGENE management will begin at 10:00 a.m. EDT (7:00 a.m.
PDT). 

To listen to a live or archived version of the audio webcast, please log on to
the Company's website, www.oxigene.com. Under the "Investor" tab, select the
link to "Events and Presentations". 

OXiGENE's earnings conference call can also be heard live by dialing
888-204-4517 in the United States and Canada, and 913-312-0714 for
international callers, five minutes prior to the beginning of the call. A
replay will be available starting at 1:00 p.m., EDT (10:00 a.m., PDT) on July
30, 2009 and ending at 12:00 midnight EDT (9:00 p.m., PDT) on Thursday, August
13, 2009. To access the replay, please dial (888) 203-1112 if calling from the
United States or Canada, or (719) 457-0820 from international locations. Please
refer to replay pass code 6002745. 

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The Company's major focus is
developing vascular disrupting agents (VDAs) that selectively disrupt abnormal
blood vessels associated with solid tumor progression and visual impairment.
OXiGENE is dedicated to leveraging its intellectual property and therapeutic
development expertise to bring life-extending and life-enhancing medicines to
patients. 

The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969 

CONTACT:  OXiGENE, Inc.
          Investor and Media Contact:
          Michelle Edwards, Investor Relations
          650-635-7006
          medwards@oxigene.com